Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

3.

Comparison of Ezetimibe/Simvastatin 10/20 mg Versus Atorvastatin 20 mg in Achieving a Target Low Density Lipoprotein-Cholesterol Goal for Patients With Very High Risk.

Cho YK, Hur SH, Han CD, Park HS, Yoon HJ, Kim H, Nam CW, Kim YN, Kim KB, Park NH, Park HJ.

Korean Circ J. 2011 Mar;41(3):149-53. doi: 10.4070/kcj.2011.41.3.149. Epub 2011 Mar 31.

4.

Validation of human ApoB and ApoAI immunoturbidity assays for non-human primate dyslipidemia and atherosclerosis research.

Chen Z, Strack AM, Stefanni AC, Chen Y, Wu W, Pan Y, Urosevic-Price O, Wang L, McLaughlin T, Geoghagen N, Lassman ME, Roddy TP, Wong KK, Hubbard BK, Flattery AM.

J Cardiovasc Transl Res. 2011 Jun;4(3):373-83. doi: 10.1007/s12265-011-9264-4. Epub 2011 Mar 11.

PMID:
21394531
5.

Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence.

Hermans MP, Sacks FM, Ahn SA, Rousseau MF.

Cardiovasc Diabetol. 2011 Feb 28;10:20. doi: 10.1186/1475-2840-10-20.

6.

log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males.

Hermans MP, Ahn SA, Rousseau MF.

Cardiovasc Diabetol. 2010 Dec 14;9:88. doi: 10.1186/1475-2840-9-88.

7.

Apolipoprotein measurements: is more widespread use clinically indicated?

Davidson MH.

Clin Cardiol. 2009 Sep;32(9):482-6. doi: 10.1002/clc.20559. Review.

8.
9.

Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices.

Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnick GR; AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices.

Clin Chem. 2009 Mar;55(3):407-19. doi: 10.1373/clinchem.2008.118356. Epub 2009 Jan 23.

10.

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).

Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN.

Clin Chem. 2009 Mar;55(3):473-80. doi: 10.1373/clinchem.2008.111401. Epub 2009 Jan 15.

11.

Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.

Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL.

J Am Coll Cardiol. 2008 Apr 15;51(15):1512-24. doi: 10.1016/j.jacc.2008.02.034. Review. No abstract available.

13.

Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels.

Marcovina S, Packard CJ.

J Intern Med. 2006 May;259(5):437-46. Review.

14.

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KM.

J Intern Med. 2006 Mar;259(3):247-58.

15.

Should we measure routinely the LDL peak particle size?

Rizzo M, Berneis K.

Int J Cardiol. 2006 Feb 15;107(2):166-70. Review.

PMID:
16412793
16.
17.

Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.

Hobbs FD.

Int J Cardiol. 2006 Jun 16;110(2):137-45. Epub 2005 Nov 11. Review.

PMID:
16289373
18.

Comparison of the relationships between serum apolipoprotein B and serum lipid distributions.

Kim BJ, Hwang ST, Sung KC, Kim BS, Kang JH, Lee MH, Park JR.

Clin Chem. 2005 Dec;51(12):2257-63. Epub 2005 Oct 7.

19.

Association between plasma lipids, and apolipoproteins and coronary artery disease: a cross-sectional study in a low-risk Korean population.

Kim HK, Chang SA, Choi EK, Kim YJ, Kim HS, Sohn DW, Oh BH, Lee MM, Park YB, Choi YS.

Int J Cardiol. 2005 Jun 8;101(3):435-40.

PMID:
15907412
20.

Optimal management of hyperlipidemia in primary prevention of cardiovascular disease.

Raza JA, Babb JD, Movahed A.

Int J Cardiol. 2004 Dec;97(3):355-66. Review.

PMID:
15561319

Supplemental Content

Support Center